NCT00912288TERMINATEDanonymous

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease

Sponsor

Source record

Pfizer

Phase

Source record

Phase 3

Modality

AI-normalized

small molecule

Target

AI-normalized

Dimebon (latrepirdine) is believed to act on multiple targets, including NMDA receptors and mitochondrial function, although its precise molecular mechanism remains unclear.

Indication / condition

AI-normalized

Alzheimer Disease

Intervention

Source record

Dimebon 20 mg po TID, Placebo po TID

Related intelligence directories

Indication directory: Alzheimer Disease Modality directory: small molecule Target directory: Dimebon (latrepirdine) is believed to act on multiple targets

Source & freshness

Source record

NCT ID

NCT00912288

Original source

ClinicalTrials.gov

Source last updated

Oct 02, 2012

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00912288

Title

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease

Sponsor

Pfizer

Status

TERMINATED

Phase

Phase 3

Condition raw

Alzheimer Disease

Condition normalized

Alzheimer Disease

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Dimebon (latrepirdine) is believed to act on multiple targets, including NMDA receptors and mitochondrial function, although its precise molecular mechanism remains unclear.

Target normalized

Dimebon (latrepirdine) is believed to act on multiple targets, including NMDA receptors and mitochondrial function, although its precise molecular mechanism remains unclear.

Interventions

Dimebon 20 mg po TID, Placebo po TID

Public preview

Source record

Dimebon was evaluated in a Phase 3 trial for moderate-to-severe Alzheimer's disease, a significant market with high unmet needs. The trial was terminated due to a lack of demonstrated efficacy in prior studies, specifically the DIM14 study. This raises concerns regarding the viability of Dimebon as a treatment option in a competitive landscape dominated by established therapies like memantine and donepezil. The termination may impact Pfizer's strategic positioning in the Alzheimer's market and necessitates a reassessment of their pipeline and investment in alternative candidates.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT00912288

Status

TERMINATED

Phase

Phase 3

Sponsor

Pfizer

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedOct 02, 2012

Internal syncJun 18, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00912288

Indication

Alzheimer Disease

Modality

small molecule

Target

Dimebon (latrepirdine) is believed to act on multiple targets, including NMDA receptors and mitochondrial function, although its precise molecular mechanism remains unclear.

Intervention

Dimebon 20 mg po TID, Placebo po TID

Source record